(MENAFNEditorial)
Canada will continue to support markedly above regional average rewards for drugmakers well into the forecast period. Rising consumption of high value pharmaceuticals and biologics stems from a mature population with above OECD average disposal income and a high incidence of chronic non-communicable disease. However growing patient prescriber and regulatory acceptance of biosimilar treatments will serve to significantly threaten the trajectory of modest growth into which Canadian pharmaceutical sales value had settled.
Headline Expenditure Projections
* Pharmaceuticals: CAD22.9bn (USD20.75bn) in 2014 to CAD23.39bn (USD19.49bn) in 2015; +2.0% in local currency terms and -6.1% in US dollar terms. Forecast revised down from Q215 .
* Healthcare: CAD210.80bn (USD190.84bn) in 2014 to CAD217.38bn (USD181.15bn) in 2015; +3.1% in local currency terms and -5.1% in US dollar terms. Forecast revised down from Q215 .
Full Report Details at
-
Risk/Reward Index
In BMI's Pharmaceuticals & Healthcare Risk/Reward Index (RRI) while Canada scores 69.9 out of 100 down from 71.1 in Q215 it retains its position as the second-most attractive market in the region after the US.
Key Trends A nd Developments
* Published in April 2015 the results of a study by Donna Graham oncologist at the Princess Margaret Cancer Centre in Toronto suggested that the vaccination of boys with the human papillomavirus (HPV) vaccine may help prevent throat cancer saving the Canadian healthcare system millions in long-term treatment costs. While Canada had previously recommended the HPV vaccine for adolescent boys the public health system only covered the vaccine costs for young girls. The analysis found that the Canadian healthcare system would likely save CAD8mn (USD6mn) to CAD28mn (USD22mn) for every 192000 boys inoculated.
* In March 2015 Health Canada announced the approval of Hospira's Inflectra (infliximab) the country's first subsequent entry biologic (SEB) monoclonal antibody therapy to treat...
The Canada Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Canada Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Canada pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Canada to test other views - a key input for successful budgeting and strategic business planning in the Canadian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Canadian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Canada.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.